Figure 1.
Enrollment Summary.
Table 1.
Baseline Demographic Characteristics (Safety Population).
Table 2.
Overall Summary of Adverse Events (Safety Population).
Table 3.
Treatment-emergent Adverse Events by System Organ Class and Preferred Term (Safety Population).
Figure 2.
Change in absolute neutrophil count from baseline.
Figure 3.
Change in total white blood cell count (WBC) from baseline.
Figure 4.
Change in total white blood cell count (WBC) in the two subjects with marked leukocytosis.
Figure 5.
Observed and model-predicted plasma concentrations of GMI-1070 after intravenous infusion.
Figure 6.
Mean change in RBC velocity as measured by computer-assisted intravital microscopy.
Table 4.
Biomarker Results